Medical Director, Mercy Hospital Oncology/Hematology

Oncology

Dr. Roger C. Inhorn, MD

Roger Inhorn works in the field of Oncology. He attended Washington University School of Medicine in St. Louis. Roger Inhorn is a published physician as well. He has 2 publications published. The latest was: Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Roger C. Inhorn accepts all Medicare patients.

Publications

Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung Cancer.

Schools

Washington Center School of Medicine
Brigham And Womans Hospital
Dana Farber Cancer Institute
Harvard University

Procedures Preformed

Thoracentesis

Conditions Treated

Acute Leukemia
Adrenal Gland Cancer
Anal and Rectal Cancer
Anemia
View All

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Education

Brigham and Women's Hospital
Washington University School of Medicine in St. Louis

Drug Facts

NPI NUMBER		1831137405
NPPES Provider LastName		INHORN
NPPES Provider FirstName		ROGER
NPPES Provider ZIPCode		041022780
NPPES Provider State		ME
Specialty Description		Hematology/Oncology
Total Claim Count		1110.0
Distinct Opioid Count		5.0
Opioid Claim Count		191.0
Percent Opioid Claims		17.21

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1831137405
Last Name Of The Provider	INHORN
First Name Of The Provider	ROGER
View All

Similar Doctors

Dr. Sarah L. Ketchum, MD

This Doctor is OpenDoctor Recommended.